![Steen Klysner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Steen Klysner
Plus aucun poste en cours
Provenance du réseau au premier degré de Steen Klysner
Entité | Type d'entité | Industrie | |
---|---|---|---|
Amarna Therapeutics BV
![]() Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.
2
| Holding Company | Medical/Nursing Services | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Steen Klysner via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
University of Leiden | College/University | Doctorate Degree | |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
SomantiX BV
![]() SomantiX BV Miscellaneous Commercial ServicesCommercial Services SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands. | Miscellaneous Commercial Services | Chief Executive Officer | |
CellProthera SAS
![]() CellProthera SAS Medical/Nursing ServicesHealth Services CellProthera SAS operates as a holding company with interests in medical studies on heart diseases. The firm focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing antilogous adult stem cells sampled directly from the patient. The company was founded by Philippe H?non in April 2008 and is headquartered in Mulhouse, France. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer |
Statistiques
Internationale
Pays-Bas | 4 |
France | 2 |
Sectorielle
Consumer Services | 2 |
Health Technology | 2 |
Commercial Services | 2 |
Health Services | 2 |
Opérationnelle
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Corporate Officer/Principal | 1 |
Relations les plus connectées
- Bourse
- Insiders
- Steen Klysner
- Connexions Sociétés